Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Alnylam Pharmaceuticals
Pharmaceutical Preparation ManufacturingUnited StatesNASDAQ: ALNY
Last verified 1 month agoalnylam.com
Alnylam Pharmaceuticals, a leader in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2002, the company has made significant strides in the development of RNA interference (RNAi) therapeutics, focusing on rare genetic diseases and other serious conditions.
With a robust pipeline of innovative products, Alnylam's core offerings include ONPATTRO® and GIVLAARI®, which are designed to address unmet medical needs through their unique mechanisms of action. The company has established a strong market position, recognised for its pioneering role in advancing RNAi technology.
Alnylam's commitment to scientific excellence and patient-centric solutions has garnered numerous accolades, solidifying its reputation as a trailblazer in the biopharmaceutical landscape.
47
DitchCarbon score
+5 vs industry average
Alnylam Pharmaceuticals’s score of 47 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alnylam Pharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Alnylam Pharmaceuticals's reported carbon emissions
Alnylam Pharmaceuticals, a US-based pharmaceutical preparation manufacturing company, is committed to addressing its carbon footprint. In 2024, the company reported total emissions of approximately 172.3 million kg CO2e. This figure comprises about 3.8 million kg CO2e from Scope 1 emissions, approximately 8.0 million kg CO2e from Scope 2 market-based emissions, and roughly 160.4 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions include purchased goods and services (around 138.2 million kg CO2e), capital goods (approximately 6.8 million kg CO2e), and upstream transportation and distribution (about 5.1 million kg CO2e).
Looking back, in 2023, Alnylam Pharmaceuticals reported total emissions of approximately 164.8 million kg CO2e, with Scope 1 emissions at about 3.5 million kg CO2e, Scope 2 market-based emissions at roughly 9.9 million kg CO2e, and Scope 3 emissions at around 151.4 million kg CO2e. In 2022, total emissions were approximately 157.3 million kg CO2e, with Scope 1 emissions at about 4.1 million kg CO2e, Scope 2 market-based emissions at roughly 10.1 million kg CO2e, and Scope 3 emissions at around 143.1 million kg CO2e. For 2021, the company disclosed Scope 1 emissions of approximately 3.9 million kg CO2e and Scope 2 market-based emissions of about 9.1 million kg CO2e, with partial Scope 3 data including business travel (around 484,000 kg CO2e), employee commute (about 2.1 million kg CO2e), and waste generated in operations (roughly 749,000 kg CO2e). In 2020, Scope 1 emissions were approximately 3.1 million kg CO2e, Scope 2 emissions were about 8.5 million kg CO2e, and partial Scope 3 data showed business travel at approximately 913,000 kg CO2e, employee commute at around 1.6 million kg CO2e, and waste generated in operations at roughly 573,000 kg CO2e.
Alnylam has set near-term reduction targets, aiming to decrease its Scope 1 emissions by 30% from 2020 levels by 2030. Similarly, the company targets a 30% reduction in Scope 2 emissions from 2020 levels by 2030. These targets are detailed in their Corporate Responsibility Report.
Assessing Alnylam Pharmaceuticals as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Alnylam Pharmaceuticals and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Alnylam Pharmaceuticals’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
On track94%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
At risk48%
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Behind target22%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
9 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
Sign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Alnylam Pharmaceuticals1 month ago
47
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more